Newton-based Clinical Data Raises $32 Million
From New England Tech Wire | June 14, 2010
Newton, Mass. -- Clinical Data, a Newton-based developer of drug candidates for central nervous system disorders and cardiovascular diseases, announced on Monday that it has raised $32 million in a secondary public offering of stock. The company sold about 2.2 million shares priced at $14.30 each. Clinical Data said it intends to use the proceeds primarily for developing its lead therapeutic candidate for the treatment of depression, vilazodone; funding the clinical trials of its coronary vasodilator, Stedivaze, which is in Phase III development; the continued development of other products and drug candidates; and for working capital and general corporate purposes.
http://www.clda.com/
Note: At time of posting, there were no jobs listed on the CLDA site. But $32M can change all that in a heartbeat.
| Topic | Replies | Likes | Views | Participants | Last Reply |
|---|---|---|---|---|---|
| Be Self-Employed Writing Content | 0 | 0 | 308 | ||
| Work from Home Writing Articles | 0 | 0 | 136 | ||
| Band Together Seeks New Executive Director in Raleigh Area | 0 | 0 | 541 |